PittsburghV1, PubMed, Checkpoint, bibRecord, 000609

HER2 as a therapeutic target in head and neck squamous cell carcinoma.

Identifieur interne : 000609 ( PubMed/Checkpoint ); précédent : 000608; suivant : 000610

HER2 as a therapeutic target in head and neck squamous cell carcinoma.

Auteurs : Netanya I. Pollock [États-Unis] ; Jennifer R. Grandis [États-Unis]

Source :

Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2015.

RBID : pubmed:25424855

Descripteurs français

KwdFr :
- Animaux, Antinéoplasiques (pharmacologie), Antinéoplasiques (usage thérapeutique), Carcinome épidermoïde (anatomopathologie), Carcinome épidermoïde (métabolisme), Carcinome épidermoïde (traitement médicamenteux), Essais cliniques comme sujet, Humains, Récepteur ErbB-2 (antagonistes et inhibiteurs), Récepteur ErbB-2 (métabolisme), Thérapie moléculaire ciblée, Transduction du signal, Tumeurs de la tête et du cou (anatomopathologie), Tumeurs de la tête et du cou (métabolisme), Tumeurs de la tête et du cou (traitement médicamenteux), Évaluation préclinique de médicament.
MESH :
- anatomopathologie : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- antagonistes et inhibiteurs : Récepteur ErbB-2.
- métabolisme : Carcinome épidermoïde, Récepteur ErbB-2, Tumeurs de la tête et du cou.
- pharmacologie : Antinéoplasiques.
- traitement médicamenteux : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- usage thérapeutique : Antinéoplasiques.
- Animaux, Essais cliniques comme sujet, Humains, Thérapie moléculaire ciblée, Transduction du signal, Évaluation préclinique de médicament.

English descriptors

KwdEn :
- Animals, Antineoplastic Agents (pharmacology), Antineoplastic Agents (therapeutic use), Carcinoma, Squamous Cell (drug therapy), Carcinoma, Squamous Cell (metabolism), Carcinoma, Squamous Cell (pathology), Clinical Trials as Topic, Drug Evaluation, Preclinical, Head and Neck Neoplasms (drug therapy), Head and Neck Neoplasms (metabolism), Head and Neck Neoplasms (pathology), Humans, Molecular Targeted Therapy, Receptor, ErbB-2 (antagonists & inhibitors), Receptor, ErbB-2 (metabolism), Signal Transduction.
MESH :
- chemical , antagonists & inhibitors : Receptor, ErbB-2.
- chemical , metabolism : Receptor, ErbB-2.
- chemical , pharmacology : Antineoplastic Agents.
- chemical , therapeutic use : Antineoplastic Agents.
- drug therapy : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- metabolism : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- pathology : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- Animals, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Molecular Targeted Therapy, Signal Transduction.

Abstract

The majority of patients with head and neck squamous cell carcinoma (HNSCC) present with advanced-stage disease. The current standard of care is surgery followed by adjuvant radiotherapy with or without chemotherapy or chemoradiation alone. The addition of cetuximab for the treatment of patients with locally advanced or recurrent/metastatic HNSCC has improved overall survival and locoregional control; however, responses are often modest, and treatment resistance is common. A variety of therapeutic strategies are being explored to overcome cetuximab resistance by blocking candidate proteins implicated in resistance mechanisms such as HER2. Several HER2 inhibitors are in clinical development for HNSCC, and HER2-targeted therapy has been approved for several cancers. This review focuses on the biology of HER2, its role in cancer development, and the rationale for clinical investigation of HER2 targeting in HNSCC.

DOI: 10.1158/1078-0432.CCR-14-1432
PubMed: 25424855

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000738
to stream PubMed, to step Curation: 000738

Links to Exploration step

pubmed:25424855

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HER2 as a therapeutic target in head and neck squamous cell carcinoma.</title>
<author><name sortKey="Pollock, Netanya I" sort="Pollock, Netanya I" uniqKey="Pollock N" first="Netanya I" last="Pollock">Netanya I. Pollock</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Grandis, Jennifer R" sort="Grandis, Jennifer R" uniqKey="Grandis J" first="Jennifer R" last="Grandis">Jennifer R. Grandis</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. grandisjr@upmc.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25424855</idno>
<idno type="pmid">25424855</idno>
<idno type="doi">10.1158/1078-0432.CCR-14-1432</idno>
<idno type="wicri:Area/PubMed/Corpus">000738</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000738</idno>
<idno type="wicri:Area/PubMed/Curation">000738</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000738</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000738</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000738</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">HER2 as a therapeutic target in head and neck squamous cell carcinoma.</title>
<author><name sortKey="Pollock, Netanya I" sort="Pollock, Netanya I" uniqKey="Pollock N" first="Netanya I" last="Pollock">Netanya I. Pollock</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Grandis, Jennifer R" sort="Grandis, Jennifer R" uniqKey="Grandis J" first="Jennifer R" last="Grandis">Jennifer R. Grandis</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. grandisjr@upmc.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title>
<idno type="ISSN">1078-0432</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antineoplastic Agents (pharmacology)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Carcinoma, Squamous Cell (drug therapy)</term>
<term>Carcinoma, Squamous Cell (metabolism)</term>
<term>Carcinoma, Squamous Cell (pathology)</term>
<term>Clinical Trials as Topic</term>
<term>Drug Evaluation, Preclinical</term>
<term>Head and Neck Neoplasms (drug therapy)</term>
<term>Head and Neck Neoplasms (metabolism)</term>
<term>Head and Neck Neoplasms (pathology)</term>
<term>Humans</term>
<term>Molecular Targeted Therapy</term>
<term>Receptor, ErbB-2 (antagonists & inhibitors)</term>
<term>Receptor, ErbB-2 (metabolism)</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antinéoplasiques (pharmacologie)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Carcinome épidermoïde (anatomopathologie)</term>
<term>Carcinome épidermoïde (métabolisme)</term>
<term>Carcinome épidermoïde (traitement médicamenteux)</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Récepteur ErbB-2 (antagonistes et inhibiteurs)</term>
<term>Récepteur ErbB-2 (métabolisme)</term>
<term>Thérapie moléculaire ciblée</term>
<term>Transduction du signal</term>
<term>Tumeurs de la tête et du cou (anatomopathologie)</term>
<term>Tumeurs de la tête et du cou (métabolisme)</term>
<term>Tumeurs de la tête et du cou (traitement médicamenteux)</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptor, ErbB-2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptor, ErbB-2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur ErbB-2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Récepteur ErbB-2</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Clinical Trials as Topic</term>
<term>Drug Evaluation, Preclinical</term>
<term>Humans</term>
<term>Molecular Targeted Therapy</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Thérapie moléculaire ciblée</term>
<term>Transduction du signal</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The majority of patients with head and neck squamous cell carcinoma (HNSCC) present with advanced-stage disease. The current standard of care is surgery followed by adjuvant radiotherapy with or without chemotherapy or chemoradiation alone. The addition of cetuximab for the treatment of patients with locally advanced or recurrent/metastatic HNSCC has improved overall survival and locoregional control; however, responses are often modest, and treatment resistance is common. A variety of therapeutic strategies are being explored to overcome cetuximab resistance by blocking candidate proteins implicated in resistance mechanisms such as HER2. Several HER2 inhibitors are in clinical development for HNSCC, and HER2-targeted therapy has been approved for several cancers. This review focuses on the biology of HER2, its role in cancer development, and the rationale for clinical investigation of HER2 targeting in HNSCC.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25424855</PMID>
<DateCreated><Year>2015</Year>
<Month>02</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>09</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-0432</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>21</Volume>
<Issue>3</Issue>
<PubDate><Year>2015</Year>
<Month>Feb</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
<ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>HER2 as a therapeutic target in head and neck squamous cell carcinoma.</ArticleTitle>
<Pagination><MedlinePgn>526-33</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-14-1432</ELocationID>
<Abstract><AbstractText>The majority of patients with head and neck squamous cell carcinoma (HNSCC) present with advanced-stage disease. The current standard of care is surgery followed by adjuvant radiotherapy with or without chemotherapy or chemoradiation alone. The addition of cetuximab for the treatment of patients with locally advanced or recurrent/metastatic HNSCC has improved overall survival and locoregional control; however, responses are often modest, and treatment resistance is common. A variety of therapeutic strategies are being explored to overcome cetuximab resistance by blocking candidate proteins implicated in resistance mechanisms such as HER2. Several HER2 inhibitors are in clinical development for HNSCC, and HER2-targeted therapy has been approved for several cancers. This review focuses on the biology of HER2, its role in cancer development, and the rationale for clinical investigation of HER2 targeting in HNSCC.</AbstractText>
<CopyrightInformation>©2014 American Association for Cancer Research.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pollock</LastName>
<ForeName>Netanya I</ForeName>
<Initials>NI</Initials>
<AffiliationInfo><Affiliation>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grandis</LastName>
<ForeName>Jennifer R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo><Affiliation>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. grandisjr@upmc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P50 CA097190</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 CA077308</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P50CA097190</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01CA77308</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>11</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Cancer Res</MedlineTA>
<NlmUniqueID>9502500</NlmUniqueID>
<ISSNLinking>1078-0432</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C535575">Carcinoma, squamous cell of head and neck</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Exp Metastasis. 2012 Jan;29(1):19-25</RefSource>
<PMID Version="1">21953075</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2009;9:6</RefSource>
<PMID Version="1">19128465</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2008 Jul 15;68(14):5878-87</RefSource>
<PMID Version="1">18632642</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2014 Mar;40(2):259-70</RefSource>
<PMID Version="1">24080156</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer Res Clin Oncol. 2005 Mar;131(3):199-203</RefSource>
<PMID Version="1">15592685</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Sci. 2008 Aug;99(8):1589-94</RefSource>
<PMID Version="1">18754871</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014;9(5):e98557</RefSource>
<PMID Version="1">24853121</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Head Neck. 2007 Jul;29(7):655-64</RefSource>
<PMID Version="1">17315173</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Otolaryngol Head Neck Surg. 1995 Nov;121(11):1265-70</RefSource>
<PMID Version="1">7576473</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2001 Nov15;94(4):474-9</RefSource>
<PMID Version="1">11745431</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Otolaryngol Head Neck Surg. 2009 Oct;141(4):467-73</RefSource>
<PMID Version="1">19786214</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2002 Feb;8(2):540-8</RefSource>
<PMID Version="1">11839675</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Mar 1;28(7):1138-44</RefSource>
<PMID Version="1">20124182</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anticancer Res. 2012 Aug;32(8):3191-9</RefSource>
<PMID Version="1">22843892</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2003 Mar 15;63(6):1179-82</RefSource>
<PMID Version="1">12649172</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Oral Pathol Med. 2008 Mar;37(3):145-50</RefSource>
<PMID Version="1">18251938</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Lett. 2002 Oct 28;184(2):223-30</RefSource>
<PMID Version="1">12127695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2012 Apr 15;18(8):2336-43</RefSource>
<PMID Version="1">22371453</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2000 Apr 15;86(2):269-75</RefSource>
<PMID Version="1">10738256</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Asian Pac J Cancer Prev. 2012;13(6):2891-6</RefSource>
<PMID Version="1">22938479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Exp Cell Res. 2003 Mar 10;284(1):99-110</RefSource>
<PMID Version="1">12648469</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2011 Sep 7;3(99):99ra86</RefSource>
<PMID Version="1">21900593</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2008 Apr;15(4):1193-201</RefSource>
<PMID Version="1">18172732</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Jul 5;357(1):39-51</RefSource>
<PMID Version="1">17611206</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 1999 Dec;5(12):4164-74</RefSource>
<PMID Version="1">10632356</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Head Neck. 2000 Sep;22(6):599-608</RefSource>
<PMID Version="1">10941162</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Prolif. 2007 Aug;40(4):580-94</RefSource>
<PMID Version="1">17635524</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11</RefSource>
<PMID Version="1">15158434</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>EMBO J. 1998 Jun 15;17(12):3385-97</RefSource>
<PMID Version="1">9628875</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Future Oncol. 2014 Jan;10(1):21-40</RefSource>
<PMID Version="1">24328407</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2013 Jan;63(1):11-30</RefSource>
<PMID Version="1">23335087</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oral Oncol. 1999 May;35(3):302-13</RefSource>
<PMID Version="1">10621852</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37</RefSource>
<PMID Version="1">11252954</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Cell Biol. 1996 Oct;16(10):5276-87</RefSource>
<PMID Version="1">8816440</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2013 Oct 15;19(20):5552-6</RefSource>
<PMID Version="1">23942091</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 Sep;25(9):1813-20</RefSource>
<PMID Version="1">24928832</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mod Pathol. 2012 May;25(5):637-50</RefSource>
<PMID Version="1">22222640</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 1993 Aug 1;53(15):3579-84</RefSource>
<PMID Version="1">8339264</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2006 Jul 1;12(13):4103-11</RefSource>
<PMID Version="1">16818711</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Cell Proteomics. 2013 Sep;12(9):2615-22</RefSource>
<PMID Version="1">23653450</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncogene. 2008 Jun 26;27(28):3944-56</RefSource>
<PMID Version="1">18297114</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Cancer Ther. 2013 Aug;12(8):1515-25</RefSource>
<PMID Version="1">23723125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 1997 Jan;3(1):3-9</RefSource>
<PMID Version="1">9815530</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8</RefSource>
<PMID Version="1">12853564</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2008 Aug;30(8):1426-47</RefSource>
<PMID Version="1">18803986</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Iran J Otorhinolaryngol. 2012 Fall;24(69):161-70</RefSource>
<PMID Version="1">24303404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 1981 Mar 19;290(5803):261-4</RefSource>
<PMID Version="1">7207618</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Invest. 2010 Jun;28(5):495-500</RefSource>
<PMID Version="1">20014947</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2011 Aug 23;105(5):618-27</RefSource>
<PMID Version="1">21829197</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Sep 15;17(18):5935-44</RefSource>
<PMID Version="1">21791633</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Front Biosci. 2002 Sep 1;7:d1926-40</RefSource>
<PMID Version="1">12161338</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncol Rep. 2010 Apr;23(4):957-63</RefSource>
<PMID Version="1">20204279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Elife. 2013;2:e00708</RefSource>
<PMID Version="1">23878723</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2002 Dec 15;62(24):7350-6</RefSource>
<PMID Version="1">12499279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2012 Apr;38(2):133-42</RefSource>
<PMID Version="1">21549508</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2010 Oct;21 Suppl 7:vii252-61</RefSource>
<PMID Version="1">20943624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Jun 1;25(16):2171-7</RefSource>
<PMID Version="1">17538161</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource>
<PMID Version="1">24101045</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncogene. 2008 Aug 7;27(34):4702-11</RefSource>
<PMID Version="1">18408761</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Head Neck. 2003 Oct;25(10):864-72</RefSource>
<PMID Version="1">12966511</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2001 Sep 1;61(17):6583-91</RefSource>
<PMID Version="1">11522658</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 1998 Jun 3;90(11):824-32</RefSource>
<PMID Version="1">9625170</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 1985 Dec 6;230(4730):1132-9</RefSource>
<PMID Version="1">2999974</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS644451</OtherID>
<OtherID Source="NLM">PMC4315724</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>11</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>11</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25424855</ArticleId>
<ArticleId IdType="pii">1078-0432.CCR-14-1432</ArticleId>
<ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1432</ArticleId>
<ArticleId IdType="pmc">PMC4315724</ArticleId>
<ArticleId IdType="mid">NIHMS644451</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Pollock, Netanya I" sort="Pollock, Netanya I" uniqKey="Pollock N" first="Netanya I" last="Pollock">Netanya I. Pollock</name>
</region>
<name sortKey="Grandis, Jennifer R" sort="Grandis, Jennifer R" uniqKey="Grandis J" first="Jennifer R" last="Grandis">Jennifer R. Grandis</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000609 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000609 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:25424855
   |texte=   HER2 as a therapeutic target in head and neck squamous cell carcinoma.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:25424855" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a PittsburghV1

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

HER2 as a therapeutic target in head and neck squamous cell carcinoma.

HER2 as a therapeutic target in head and neck squamous cell carcinoma.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki